Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma
- Author
- Nora Sundahl, Katrien De Wolf, Vibeke Kruse (UGent) , Annabel Meireson (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Mireille Van Gele (UGent) , Reinhart Speeckaert (UGent) , Benjamin Hennart, Lieve Brochez (UGent) and Piet Ost (UGent)
- Organization
- Keywords
- LATE-ONSET TOXICITIES, BRAIN METASTASES, CHECKPOINT INHIBITORS, T-CELLS, IMMUNOTHERAPY, RADIOTHERAPY, TUMORS, RESISTANCE, CANCER, RADIOSURGERY
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 417.87 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8566831
- MLA
- Sundahl, Nora et al. “Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 100.4 (2018): 906–915. Print.
- APA
- Sundahl, N., De Wolf, K., Kruse, V., Meireson, A., Reynders, D., Goetghebeur, E., Van Gele, M., et al. (2018). Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(4), 906–915.
- Chicago author-date
- Sundahl, Nora, Katrien De Wolf, Vibeke Kruse, Annabel Meireson, Dries Reynders, Els Goetghebeur, Mireille Van Gele, et al. 2018. “Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.” International Journal of Radiation Oncology Biology Physics 100 (4): 906–915.
- Chicago author-date (all authors)
- Sundahl, Nora, Katrien De Wolf, Vibeke Kruse, Annabel Meireson, Dries Reynders, Els Goetghebeur, Mireille Van Gele, Reinhart Speeckaert, Benjamin Hennart, Lieve Brochez, and Piet Ost. 2018. “Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.” International Journal of Radiation Oncology Biology Physics 100 (4): 906–915.
- Vancouver
- 1.Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, et al. Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2018;100(4):906–15.
- IEEE
- [1]N. Sundahl et al., “Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma,” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 100, no. 4, pp. 906–915, 2018.
@article{8566831,
author = {Sundahl, Nora and De Wolf, Katrien and Kruse, Vibeke and Meireson, Annabel and Reynders, Dries and Goetghebeur, Els and Van Gele, Mireille and Speeckaert, Reinhart and Hennart, Benjamin and Brochez, Lieve and Ost, Piet},
issn = {0360-3016},
journal = {INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS},
keywords = {LATE-ONSET TOXICITIES,BRAIN METASTASES,CHECKPOINT INHIBITORS,T-CELLS,IMMUNOTHERAPY,RADIOTHERAPY,TUMORS,RESISTANCE,CANCER,RADIOSURGERY},
language = {eng},
number = {4},
pages = {906--915},
title = {Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma},
url = {http://dx.doi.org/10.1016/j.ijrobp.2017.11.029},
volume = {100},
year = {2018},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: